#USA #Berlin #Aignostics #tumor profiling #Atlas HE-TME

Aignostics Unveils Atlas HE-TME

In a groundbreaking development in cancer research, Aignostics has officially launched their brand new AI-powered application, Atlas HE-TME. Following successful pilot projects with leading biopharmaceutical partners, this application is designed to significantly enhance the profiling of tumor microenvironments (TME) from hematoxylin-eosin (HE) stained images.

Addressing Critical Bottlenecks in Cancer Research

Cancer research has often faced bottlenecks due to the limitations of traditional methods, which can be costly and time-consuming. Atlas HE-TME aims to alleviate these challenges by providing rapid and in-depth analysis of HE slides without the need for additional staining or multiplexing technologies. This application can analyze whole-slide images within hours, enabling researchers to quickly characterize immune cell populations and their spatial relationships within various cancer types.

The development of Atlas HE-TME is the result of a collaboration between Aignostics, the Mayo Clinic, and the Charité Hospital in Berlin. The application delivers robust quality control metrics, differentiating between seven types of tissue and nine classes of cells while yielding over 5,000 high-order quantitative measurements per image.

A Paradigm Shift in Tumor Microenvironment Understanding

Frederick Klauschen, MD, co-founder of Aignostics and director at the Ludwig Maximilians University of Munich’s Institute of Pathology, has expressed his enthusiasm for how this model operates with high precision across multiple cancer indications. He stated, “This is the first time I have seen a model exhibit high and consistent accuracy across various cancer types.” Viktor Matyas, another co-founder and CEO of Aignostics, highlighted the importance of understanding tumor microenvironments as crucial for effective cancer therapy development.

“The classic approaches can be expensive and labor-intensive, often limiting scalability,” Matyas noted. “Atlas HE-TME is revolutionizing this paradigm. Our pilot projects with the biopharmaceutical industry demonstrate that we can provide high-quality results with unmatched accuracy, speed, and scalability—helping researchers maximize the value from each HE image.”

A Versatile Tool for Comprehensive Research

Atlas HE-TME supports a range of research applications, including the swift identification and characterization of immune-infiltrated tumors. Additionally, it allows for the integration of HE data with spatial transcriptomics for refined analysis of cellular niches. Initially, the application will be available for biopharmaceutical partners focusing on breast, bladder, colorectal, liver, and lung cancers. Academic access will expand in the coming months, potentially including additional cancer types and analyses. Interested organizations can find more information and request a free trial on the Aignostics website.

About Aignostics

Founded in 2020, Aignostics is an artificial intelligence company that transforms complex multimodal pathological data into actionable insights for precision medicine. Emerging from the Charité Berlin, Aignostics combines exclusive access to clinical multimodal data, cutting-edge AI technologies, and rigorous scientific research to deliver top-tier products and services throughout the drug development journey—from discovery through to clinical trials and companion diagnostics, as well as translational research.

The newly launched Atlas HE-TME application is a testament to Aignostics' commitment to enabling researchers by providing unprecedented precision and scalability in tumor microenvironment profiling. With over 120 employees and operations in Berlin and New York, Aignostics is backed by prominent investors. For further details, visit Aignostics' Official Website and follow them on LinkedIn.